The Canadian government has barred Teva Pharmaceuticals USA, the American arm of the global generic drug manufacturer Teva Pharmaceuticals, from entering into federal contracts until spring 2025. This decision is a consequence of the company’s involvement in a “domestic antitrust cartel” in the United States, leading to a US$225-million criminal penalty.
Featured News
Live Nation Faces Growing UK Antitrust Pressure Over Industry Influence
Jul 20, 2026 by
CPI
Buchanan Ingersoll Expands Antitrust Practice With Washington Hire
Jul 20, 2026 by
CPI
China Nears Decision in Antitrust Case Against Trip.com
Jul 20, 2026 by
CPI
EU Intensifies Cartel Probe Into Swiss Chemicals Firm Sika
Jul 20, 2026 by
CPI
X and Major Music Publishers Settle Parallel Copyright and Antitrust Cases
Jul 20, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes